MRI May Define Two Distinct Migraine Phenotypes - Summary - MDSpire

MRI May Define Two Distinct Migraine Phenotypes

Patients with greater migraine burden showed widespread connectivity changes and lower cortical volume.

  • By

  • Andrea Surnit

  • May 21, 2026

  • 3 min

Share

Objective:

To investigate the potential of neuroimaging to separate migraine patients into distinct subgroups based on clinical and imaging profiles.

Key Findings:
  • Ensure all findings are presented as stated in the source without additional interpretation.
Interpretation:

Remove the interpretation section.

Limitations:
  • Modest sample size and cross-sectional design limited assessment of subgroup stability over time.
  • Migraine phase during imaging and preventive medication use were not systematically recorded.
  • The study was not designed to compare imaging-based subgrouping with clinical-only subgrouping approaches.
Conclusion:

The study applied a data-driven integration of functional and structural MRI features to characterize heterogeneity within migraine.

Original Source(s)

MRI May Define Two Distinct Migraine Phenotypes

  • by Andrea Surnit

  • May 21, 2026

Related Content

2026 Brain and Spine Symposium Highlights Advances Across the Neurosciences

Over two days, specialists across neurology, neurosurgery and related subspecialties came together to discuss advances in stroke care, epilepsy, movement disorders, neurodegenerative disease, neuro-oncology, brain and spine surgery, interventional pain management and emerging technologies.

  • by

  • May 21, 2026

  • 1 min
Baptist Health Foundation Presents Endowed Chair Ceremony for Aviva Abosch, M.D., Ph.D.

Aviva Abosch, M.D., Ph.D., a neurosurgeon at Baptist Health Miami Neuroscience Institute, part of Baptist Health Brain and Spine Care, was installed as the Esernia Endowed Chair in Surgical Treatment of Adult Epilepsy and Movement Disorders.

  • by

  • May 21, 2026

  • 5 min
CGRP Therapies Reduced Migraine Days

Systematic review found high-certainty evidence for several calcitonin gene–related peptide–targeted therapies